Bioequivalence Between an Ibuprofen Suspension and a Reference Formulation. A Study in Healthy Volunteers.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- McNeil AB
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- AUCt
研究概览
简要总结
This study is designed to assess bioequivalence between one test and one reference formulation used for temporary relief of pain. The results will help decide if the new medicine is likely to provide pain relief similar to the product being sold.
详细描述
The study is a single dose, randomized, two-way crossover study in 32 healthy male and female volunteers, minimum of 14 of each gender. Two doses of study medication will be given as single doses on two separate treatment visits. A washout of at least 48 hours will separate the treatment visits. Each visit will include an overnight fast at the clinic and 19 blood samples drawn for pharmacokinetic analyses. Tolerability of the treatments will be evaluated in terms of reported and observed adverse events (AE).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy (per protocol-specified parameters) male or female subjects (14 of each gender) between the ages of 18 and 50 years, inclusive.
- •Non- or ex-tobacco user, being defined as someone who completely stopped smoking or using any form of tobacco for at least 12 months before screening visit of this study.
- •For females: if not postmenopausal, agrees to use a protocol-specified means of contraception or declared absence of sexual contact with a male partner during the study.
- •For males: No pregnant spouse or partner at screening and willingness to protect potential spouse or partner from becoming pregnant during the study.
- •Body Mass Index (BMI) within protocol-specified parameters.
- •A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
- •Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol.
排除标准
- •Evidence or history of an acute or chronic medical or psychiatric condition, laboratory abnormality, or drug use that, in the judgment of the investigator or an authorized physician, may compromise subject safety or the interpretation of results.
- •Females: Pregnant or breast-feeding
- •Treatment with an investigational drug within 3 months preceding the first dose of study treatment.
- •History of regular alcohol consumption outside the protocol-specified allowances.
- •Donation or loss of blood within 3 months prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 450 mL.
- •Relationship to persons involved directly with the conduct of the study, or their families.
研究组 & 干预措施
A-IBU
A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits.
干预措施: Ibuprofen (Drug)
B-IBU
A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
干预措施: Ibuprofen (Drug)
结局指标
主要结局
AUCt
时间窗: During 12 hours post-dose
Area under the plasma concentration-vs.-time curve from start of drug administration until last measured concentration (AUCt), is a measure of how much of the drug reaches the bloodstream during the sampling period.
Cmax
时间窗: During 12 hours post-dose
Maximum observed plasma concentration (Cmax), is the maximum (peak) concentration (amount of drug) measured in blood plasma after a dose administration.
次要结局
- tmax(During 12 hours post-dose)
- t½(During 12 hours post-dose)
- Mean Residence Time (MRT)(During 12 hours post-dose)
- AUC∞(During 12 hours post-dose)
- Terminal Elimination Rate Constant (λz)(During 12 hours post-dose)